Application
Anti-EGFR, clone 11E19 ZooMAb, Cat. No. ZRB04338, is a recombinant Rabbit Monoclonal Antibody that detects epidermal growth factor receptor (EGFR) and has been tested for use in Immunocytochemistry Immunohistochemistry (Paraffin), RNAi/siRNA/Gene Knockdown Analysis, and Western Blotting.
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected EGFR in A431 cell lysate.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected EGFR in HeLa, A431, HUVEC, and NIH 3T3 cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected EGFR in human placenta tissue sections.RNAi/siRNA/Gene Knockdown Analysis: A 1:250 dilution from a representative lot detected EGFR lysates from wild type and EGFR knockout HeLa cells.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.
Immunogen
KLH-conjugated linear peptide corresponding to 30 amino acids from the C-terminal region of human Epidermal growth factor receptor.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
30 µg/mL after reconstitution at 25 µL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Specificity
Clone 11E19 is a ZooMAb rabbit recombinant monoclonal antibody that detects human and murine Epidermal Growth Factor Receptor. It targets an epitope with in 30 amino acids from the C-terminal region.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Target description
Epidermal growth factor receptor (UniProt: P00533; also known as EC: 2.7.10.1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1) is encoded by the EGFR (also known as ERBB, ERBB1, HER1) gene (Gene ID: 1956) in human. EGFR is a single-pass type 1 membrane protein that is ubiquitously expressed. It is synthesized with a 24 amino acids signal peptide that is subsequently cleaved off. The mature form contains an extracellular domain (aa 25-645) a transmembrane domain (aa 646-668), and a cytoplasmic domain (aa 669-1210). Upon binding of EGF or other ligands, the receptor undergoes homo-and/or heterodimerization that stimulates its intrinsic intracellular protein-tyrosine kinase activity and leads to autophosphorylation of tyrosine residues in the C-terminal region. It then recruits adapter proteins to turn on downstream signaling cascades. EGFR is commonly overexpressed and is mutated in many human malignancies and is often associated with aggressive phenotypes. Four different isoforms of EGFR have been described that are produced by alternative splicing. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
This product has met the following criteria to qualify for the following awards: